<code id='3FCAA119DD'></code><style id='3FCAA119DD'></style>
    • <acronym id='3FCAA119DD'></acronym>
      <center id='3FCAA119DD'><center id='3FCAA119DD'><tfoot id='3FCAA119DD'></tfoot></center><abbr id='3FCAA119DD'><dir id='3FCAA119DD'><tfoot id='3FCAA119DD'></tfoot><noframes id='3FCAA119DD'>

    • <optgroup id='3FCAA119DD'><strike id='3FCAA119DD'><sup id='3FCAA119DD'></sup></strike><code id='3FCAA119DD'></code></optgroup>
        1. <b id='3FCAA119DD'><label id='3FCAA119DD'><select id='3FCAA119DD'><dt id='3FCAA119DD'><span id='3FCAA119DD'></span></dt></select></label></b><u id='3FCAA119DD'></u>
          <i id='3FCAA119DD'><strike id='3FCAA119DD'><tt id='3FCAA119DD'><pre id='3FCAA119DD'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          knowledge

          author:fashion    - browse:4
          Alastair Grant/AP

          LONDON — AstraZeneca said Friday an experimental drug tamped down the progression of a certain type of breast cancer in a Phase 3 trial, a win for the company after the same drug produced underwhelming results in a lung cancer trial over the summer.

          The drug, called datopotamab deruxtecan or Dato-DXd for short, succeeded on one of its primary endpoints of improving progression-free survival compared to chemotherapy in certain breast cancer patients who had previously been treated with other therapies.

          advertisement

          AstraZeneca, which is developing Dato-DXd with partner Daiichi Sankyo, said that the data for the other primary endpoint of overall survival were not “mature” as of this interim analysis, but that there was a positive trend. The trial is continuing.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus